European Companies Search Engine
UK funding (£1,120,010): Development of a Scalable Manufacturing Process for a Novel Oral Infliximab Product using the Soteria Technology Ukri1 Oct 2018 UK Research and Innovation, United Kingdom
Overview
Text
Development of a Scalable Manufacturing Process for a Novel Oral Infliximab Product using the Soteria Technology
| Abstract | Though the monoclonal antibody (mAb), infliximab, is considered a gold-standard treatment for the 300,000 patients in the UK with inflammatory bowel disease (IBD), the compound can only be administered through an inconvenient and often painful injection. In doing so, only less than 1% of the drug reaches the site of disease, limiting the efficacy of the treatment whilst causing a wide range of serious side-effects. Intract Pharma's novel drug delivery technology, Soteria, allows for infliximab to be administered orally, creating a more targeted IBD treatment. In partnership with the Centre for Process Innovation (CPI), Quay Pharmaceuticals and Pharmidex, Intract Pharma will develop, optimise and validate a manufacturing process that enables mAbs to be formulated as an oral solid dosage form, and in turn create a GMP-ready manufacturing protocol for Soteria. So far, mAb therapies have not yet been able to be manufactured for oral administration in both a clinically and commercially viable manner. Therefore, the project will develop new innovative manufacturing approaches in the field of pharmaceutical formulation, particularly with regards to antibody stabilisation and formulation. As a result, this project will not only break new ground in antibody formulation but further develop a therapeutic that could vastly improve the treatment of patients with IBD. |
| Category | Collaborative R&D |
| Reference | 104519 |
| Status | Closed |
| Funded period start | 01/10/2018 |
| Funded period end | 30/09/2021 |
| Funded value | £1,120,010.00 |
| Source | https://gtr.ukri.org/projects?ref=104519 |
Participating Organisations
| INTRACT PHARMA LIMITED |
£420,330.00 |
| PHARMIDEX PHARMACEUTICAL SERVICES LIMITED |
£186,825.00 |
| CENTRE FOR PROCESS INNOVATION LIMITED |
£415,687.00 |
| QUAY PHARMACEUTICALS LIMITED |
£97,168.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Intract Pharma Ltd., Cambridge.
The visualizations for "Intract Pharma Ltd. - UK funding (£1,120,010): Development of a Scalable Manufacturing Process for a Novel Oral Infliximab Product using the Soteria Technology"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
